Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company's product portfolio includes Mitazalimab, an agonistic antibody that targets CD40, which is in phase 2 clinical trail for the treatment solid metastatic tumors, initially pancreatic cancer; and ATOR-4066, a bispecific antibody tumor-specific immune effect, developed using Neo-X-Prime technology platform for colorectal, gastric, and pancreatic cancer, which is in preclinical stage. It also offers ATOR-1017, a 4-1BB for solid metastatic tumors which is in Phase 1 clinical trial; and ALG.

APV-527, a preclinical stage drug that target tumor-associated antigen 4-1BB and 5T4. In addition, the company develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. Further, it has collaboration and out-licensing agreements with Aptevo Therapeutics, Inc.; Orion Corporation.; MacroGenics, Inc.; Biotheus; and Abclon.

The company was incorporated in 2000 and is headquartered in Lund, Sweden.